Your vision, our versatility.
RQM+ offers two delivery models to align with your project's needs and ensure optimal outcomes.
We currently offer this for clinical evaluation, performance evaluation, post-market surveillance, and post-marketing clinical follow-up deliverables associated with EU MDR and IVDR.
Our Full Service model is the gold standard for clients seeking a robust support system for EU MDR and IVDR clinical regulatory affairs challenges and is the best model for most clients. It offers comprehensive project management, strategic guidance, and an individual or team of technical experts.
Ideal for clients who require:
– In-depth project management
– Strategic insights
– Collaborative team approach
– Support for complex regulatory situations
With Value+, experience a streamlined yet powerful approach to creating EU MDR and IVDR clinical affairs documents. Offering senior-level expertise at 30% less cost than our Full Service model, Value+ is ideal for clients who need:
– High-quality, cost-efficient documents
– Senior-level expertise without additional subject matter expert and project management support
– Solutions for straightforward regulatory needs
Clients who meet the following criteria are typically a great fit for Value+:
– Have a limited budget
– Just want a document and a writer
– Have final input documents available
– Able to commit to an efficient timeline
We offer this service for document updates, as well as new documents.
Our experts will help you develop a clinical evaluation strategy to achieve your business objectives and notified body approval.
We provide innovative strategies for using existing data along with your PMCF plan based upon our experience with a wide range of notified bodies.
From CEPs to SSCPs, we enable you to tell a compelling story, making your documentation appealing to regulators.
Our integrated approach reduces time to certification with fewer notified body questions and nonconformities.
CERs cannot be created in a bubble by the clinical team. There are inputs and outputs between clinical, post-market surveillance, and risk management. Integrating the processes optimizes resources and reduces the risk of audit findings. Our experts will help you update and revise your quality system so that all your processes are working together efficiently. This will ensure that you can meet the requirements of the MDR now and in the future.
The notified body may not interpret the MDR's requirements in the same way you do and you only have three rounds of Q&A to gain alignment and approval. Additionally, a deficiency that calls for more clinical data could result in an expensive study or the loss of product certification. With so much on the line, a different perspective and proposed response plan from our former notified body leaders and subject matter experts could make all the difference.
The RQM+ team will assess your CER process and documentation by product line, providing you with a detailed gap analysis and remediation plan. Our team of experts can effectively execute a remediation of any size, minimizing the burden on your team so you can maintain focus on new products.
Our CER project managers act as the single point of contact for all client needs and are responsible for leading meetings, developing schedules for deliverables, monitoring progress, and driving results. This includes actively managing the client approval process and coordinating independent review of all documentation.
For ongoing compliance, we ensure client documentation is updated as new data becomes available and then provided to notified bodies by the required deadlines.
Clinical evaluation preparation requires a deep understanding of medical devices, clinical data, and what is sufficient to prove safety, performance, and state of the art. RQM+ can take the lead so you do not have to.
Whether you need targeted support for specific tasks or comprehensive technical leadership and project management, RQM+ can help with every aspect of the clinical evaluation process.
Clinical evaluation is a continuous effort requiring integrated solutions. RQM+ is here as long as you need us.
We consistently meet reviewer expectations because we know what they want to see. Positive feedback from notified bodies proves it.
RQM+ leadership and staff includes people who have drafted MDCG guidance documents on clinical evaluation, device equivalence, and sufficient clinical evidence for legacy devices.
Entrusting your CERs to a consulting firm requires confidence in the team. With RQM+, you get a level of clinical and regulatory expertise and client dedication you won’t find anywhere else.
In MDCG 2020-6 guidance, it acknowledges that for a legacy device that's been on the market for a while, it's not appropriate to recreate the development plan because you've already been through that process. Instead, per the appendix to the guidance shows what you should have in lieu of having new clinical data, including a PMS plan.
From the NB point of view, you could write one CER that covers both the MDR and MDD requirements, and be clear so that the NB can see the delineation. This can be complicated to maintain, and require a lot of mapping and explaining, so it may be easier to separate the products.
GLOBAL BOTTOM CTA INSTRUCTIONS:
To display custom copy instead of global copy in this section, please go to Show Global Content for Bottom CTA? toggle in the "Contents" tab to the left, toggle it off, save, and then REFRESH the page editor, the custom text will then show up and ready to be edited.
Turning the global content back on will be the same process, go to the toggle and toggle it back on, save and refresh!
United States HQ 2790 Mosside Blvd. United States (U.S.) |
Europe HQ 3rd Floor, 1 Ashley Road Altrincham, Cheshire, |
©2024 RQM+ All Rights Reserved | Privacy Policy | Terms of Use